Release Date: December 5, 2025
Expiration Date: December 5, 2026
Activity Overview
The New York Lung Cancers Symposium® is a comprehensive overview of multidisciplinary lung cancer treatment. Now in its twentieth year, this meeting is designed to increase your knowledge of lung cancer therapy, including the roles that surgery, radiology, pulmonology, and pathology play, to ensure the most accurate diagnosis of lung cancers. Thought leaders from the New York area discuss optimal approaches for early-stage and locally advanced disease and present the latest data on immunotherapy and targeted agents in metastatic lung cancers. These multidisciplinary interactions are illustrated in a tumor board format, in which participants at the meeting presented questions and clinical challenges from their practices.
This educational activity is an archive of the live presentation held on November 15, 2025.
For more information about this educational activity, including
details about the faculty and their disclosures, please click here.
Partner Acknowledgment
PER® is proud to partner with the Empire State Hematology & Oncology Society, the International Association for the Study of Lung Cancer (IASLC), LUNGEVITY, and Memorial Sloan Kettering Cancer Center.
Target Audience
This educational activity is directed toward medical oncologists, along with surgeons, radiologists, general scientists, young investigators, advanced practice providers, nurses, and pharmacists who manage patients with lung cancers. Other health care professionals interested in the treatment of lung cancer are also invited to participate.
Learning Objectives
Upon successful completion of this activity, learners will be better able to:
- Evaluate emerging therapeutic targets and new biomarker testing strategies to guide precision medicine approaches for patients with lung cancers
- Assess recent efficacy and safety data from pivotal clinical trials investigating novel therapies and combination approaches for the treatment of localized and metastatic lung cancers
- Apply the latest data, guideline recommendations, and disease/patient-specific factors to optimize precision treatment approaches for patients with localized and metastatic lung cancers
- Develop evidence-based strategies to mitigate treatment-related adverse effects associated with novel therapies and combination approaches for the treatment of lung cancers
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here